

Kathryn Trinkaus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6619191/publications.pdf>

Version: 2024-02-01

35
papers

693
citations

687363

13
h-index

552781

26
g-index

35
all docs

35
docs citations

35
times ranked

1554
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying white matter tract diffusion parameters in the presence of increased extra-fiber cellularity and vasogenic edema. <i>NeuroImage</i> , 2014, 101, 310-319.	4.2	108
2	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1295-1305.	10.7	87
3	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 58, 41-48.	1.5	78
4	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	3.5	54
5	Geriatric Assessment in Older Adults with Multiple Myeloma. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 987-991.	2.6	42
6	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
7	Bone marrow dendritic cells regulate hematopoietic stem/progenitor cell trafficking. <i>Journal of Clinical Investigation</i> , 2019, 129, 2920-2931.	8.2	40
8	Axonal transport rate decreased at the onset of optic neuritis in EAE mice. <i>NeuroImage</i> , 2014, 100, 244-253.	4.2	35
9	Diffusion basis spectrum imaging provides insights into MS pathology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	25
10	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , The, 2018, 19, 1082-1093.	10.7	21
11	Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis. <i>Neurobiology of Disease</i> , 2014, 67, 1-8.	4.4	20
12	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 61, 1-7.	1.5	18
13	Diffusion basis spectrum imaging for identifying pathologies in MS subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2323-2327.	3.7	17
14	Fractional anisotropy to quantify cervical spondylotic myelopathy severity. <i>Journal of Neurosurgical Sciences</i> , 2018, 62, 406-412.	0.6	14
15	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 72, 26-31.	1.5	12
16	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3693-3693.	1.4	12
17	Intensity ratio to improve black hole assessment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 140-147.	2.0	11
18	Paired-like Homeodomain Transcription factor 2 expression by breast cancer bone marrow disseminated tumor cells is associated with early recurrent disease development. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 507-517.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27494.	1.5	8
20	Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 107-113.	2.0	8
21	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008, 112, 2595-2595.	1.4	8
22	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1623-1623.	1.4	7
23	Giving Voice to Black Men: Guidance for Increasing the Likelihood of Having a Usual Source of Care. <i>American Journal of Men's Health</i> , 2019, 13, 155798831985673.	1.6	6
24	Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 687-693.	2.0	5
25	Second primary melanomas: Increased risk and decreased time to presentation in patients exposed to tanning beds. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1101-1108.	1.2	5
26	High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability. <i>Blood</i> , 2012, 120, 4095-4095.	1.4	1
27	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2379-2380.	27.0	0
28	Threat sensitivity is associated with the healthcare source used most often: doctor's office, emergency room, or none at all. <i>Heliyon</i> , 2019, 5, e01685.	3.2	0
29	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 3127-3127.	1.4	0
30	The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide. <i>Blood</i> , 2012, 120, 4050-4050.	1.4	0
31	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. <i>Blood</i> , 2015, 126, 3106-3106.	1.4	0
32	Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. <i>Blood</i> , 2016, 128, 3419-3419.	1.4	0
33	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. <i>Blood</i> , 2016, 128, 4698-4698.	1.4	0
34	Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4203-4203.	1.4	0
35	A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2146-2146.	1.4	0